Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.65 |
| ▸ | MET | P08581 | 8/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31554522 | 1.00 | ROCK2 (0.65) | ROCK2METCYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL5097103 | 0.99 | ROCK2 (0.64) | ROCK2METCYP3A4TRPA1 | |
| SCHEMBL2877126 | 0.85 | ROCK2 (0.54) | ROCK2METCYP3A4TRPA1 | |
| SCHEMBL4817550 | 0.84 | ROCK2 (0.58) | ROCK2METCYP3A4TRPA1 | |
| SCHEMBL3485162 | 0.84 | ROCK2 (0.52) | ROCK2METCYP3A4 | |
| SCHEMBL25793147 | 0.83 | ROCK2 (0.53) | ROCK2METCYP3A4 | |
| SCHEMBL29837329 | 0.83 | ROCK2 (0.53) | ROCK2METCYP3A4 | |
| SCHEMBL29018884 | 0.83 | ROCK2 (0.58) | ROCK2METCYP3A4TRPA1 | |
| SCHEMBL4815289 | 0.81 | MET (0.61) | ROCK2MET | |
| SCHEMBL24885851 | 0.81 | ROCK2 (0.49) | ROCK2METCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | claimed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-112457295-B | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | disclosed |
| CN-110520416-B | Polysubstituted pyridone derivative, preparation method and medical application thereof | 北京越之康泰生物医药科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021043217-A1 | COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF | 中国科学院上海药物研究所 | 2021-03-11 | — | — | WO | disclosed |
| CN-112457295-A | Compound with Axl and c-Met kinase inhibitory activity and preparation and application thereof | 中国科学院上海药物研究所 | 2021-03-09 | — | — | CN | disclosed |
| CN-108341813-B | Substituted 1- (isoxazol-3-yl) -3- (3-fluoro-4-phenyl) urea derivative and preparation method and application thereof | 四川大学 | 2020-11-17 | — | — | CN | disclosed |
| CN-110520416-A | Polysubstituted pyridine ketones derivant, preparation method and its medical usage | BEIJING YUEZHIKANGTAI BIOMEDICINES CO LTD | 2019-11-29 | — | — | CN | disclosed |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | VIBLIOME THERAPEUTICS, LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2006004636-A2 | FUSED HETEROCYCLIC KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097790-A1 | HETARYLOXY-SUBSTITUTED PHENYLAMINO PYRIMIDINES AS RHO KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | WO | disclosed |
| EP-1562935-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005058891-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058891-A1 | PYRROLOPYRIDINE-SUBSTITUTED BENZOL DERIVATIVES FOR TREATING CARDIOVASCULAR DISEASES | BAYER HEALTHCARE AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | ROCK2 395/4885MET 721/4885CYP3A4 2351/4885 |
| US-20180125848-A1 | PREPARATION AND METHODS OF USE FOR ORTHO-ARYL 5-MEMBERED HETEROARYL-CARBOXAMIDE CONTAINING MULTI-TARGETED KINASE INHIBITORS | ABL1, ERBB2, MAP3K2 | ROCK2 323/4885MET 206/4885CYP3A4 2553/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | ROCK2 433/4885MET 2109/4885CYP3A4 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.